Business
Easton Pharmaceuticals Announces Formal Agreement & Advances Payment to BMV Medica S.A. Towards a Regulatory Filing in Mexico for "Viorra"; Company Anticipates Approval and Initial Sales by End of Second Quarter 2014
Easton Pharmaceuticals Announces Formal Agreement & Advances Payment to BMV Medica S.A. Towards a Regulatory Filing in Mexico for "Viorra"; Company Anticipates Approval and Initial Sales by End of Second Quarter 2014.
About this update from Easton Pharmaceuticals Inc
[{"type":"text","content":"\n \n \n Easton Pharmaceuticals Announces Formal Agreement & Advances Payment to BMV Medica S.A. Towards a Regulatory Filing in Mexico for \"Viorra\"; Company Anticipates Approval and Initial Sales by End of Second Quarter 2014\n \n \nEaston Pharmaceuticals Announces Formal Agreement & Advances Payment to BMV Medica S.A. Towards a Regulatory Filing in Mexico for \"Viorra\"; Company Anticipates Approval and Initial Sales by End of Second Quarter 2014\n \n TORONTO, ON--(Marketwired - Oct 22, 2013) - Easton Pharmaceuticals, Inc. (OTC: EAPH), a specialty pharmaceutical company that designs, develops, and markets a premium array of topically-delivered drugs and therapeutic healthcare products announced today it has signed a formal agreement with BMV Medica S.A. de C.V. (BMV) a Mexican Regulatory & Licensing consultancy to begin the process of submitting applications to obtain regulatory government approvals for its flagship product \"VIORRA.\"\n The agreement calls for milestone payments to be made to BMV and has confirmed that an initial up- front payment representing 33% (\"percent\") of the total owed, plus a consultant fee, has been advanced to BMV towards the \"VIORRA\" government regulatory filing, which represents the first such payment to BMV after previous delays. The remaining payments as per the agreement, calls for milestone payments to be made over the next 6 month period which includes the drafting and submission of a comprehensive Dossier. BMV has guaranteed to the Company, pending the receipt of appropriate manufacturing documents, the company shall receive not only regulatory approval in Mexico, but shall search and deliver on a suitable distribution partner for sales and marketing. \"Viorra\" is an over-the-counter aid meant to restore and improve vaginal moisture and elasticity which has a very positive effect on women's sexual desire and arousal targeted for women suffering from FSAD (Female Sexual Arousal Disorder). VIORRA is a topical, daily-use product formulated with ingredients classified by the FDA as Generally Recognized as Safe.\n Carla Pepe, Easton Pharmaceuticals Marketing Director / Corporate Secretary and Director, stated, \"We are pleased to have moved forward with BMV and to have them see this through on all fronts on behalf of Easton Pharmaceuticals, in Mexico and other Latin American ma...